STAT+: Medicaid transgender care rule sets precedent that could restrict coverage of other drugs
The legal theory used to restrict gender-affirming care for minors could be applied broadly, experts say.
The Trump administration has announced a new rule that may impact Medicaid coverage for various drugs, potentially setting a precedent for restricting access to medication in the future. According to the Centers for Medicare and Medicaid Services (CMS), the rule, effective October 13th, denies federal Medicaid and Children's Health Insurance Program (CHIP) funding for pediatric gender-affirming medications and surgeries.
This decision has drawn attention due to its alignment with the administration's broader efforts to limit transgender healthcare access for young individuals. However, Medicaid specialists contend that this rule could lead to broader implications, potentially undermining the expectation that Medicaid covers a wide range of prescription medications.
Typically, Medicaid covers most FDA-approved outpatient drugs with medically accepted indications, provided drug manufacturers agree to significant rebates.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
